Keith R. Bley, Ph.D., has been appointed senior vice president of Product Development at NovaBay Pharmaceuticals. Dr. Bley has more than 20 years of experience in the pharma industry, having held management positions with increasing responsibility in R&D.
 
Previously, Dr. Bley worked as a consultant to various pharma companies in the San Francisco Bay Area, assisting with a wide range of drug development activities. Prior to that, Dr. Bley was senior vice president of Nonclinical R&D at NeurogesX, where he supported all phases of drug development and gained thorough knowledge of FDA regulations and international regulatory requirements. Dr. Bley also worked as a research manager for Roche and Syntex Corp.
 
"We are very excited to welcome Keith on board to NovaBay," said Dr. Ron Najafi, chairman and chief executive officer. "We believe he brings valuable regulatory expertise both in the U.S. and abroad. Keith has worked on topical therapies, and understands the unique challenge they can represent. We are confident that he will contribute significantly to the NovaBay management team as we and our partners continue moving our lead Aganocide compound, NVC-422 or auriclosene, through three Phase II trials."